RNA — Atrium Therapeutics, Inc. Dilution Risk Tracker

Atrium Therapeutics, Inc. (RNA) has a DilutionScore of 41/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for RNA shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for RNA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for RNA alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.